雄激素受体
孕烷X受体
化学
核受体
受体
雄甾烷
药理学
体内
探地雷达
类固醇
雌激素受体
生物化学
激素
内科学
立体化学
基因
生物
癌症
转录因子
医学
生物技术
乳腺癌
作者
Ivana Mejdrová,Ján Dušek,Kryštof Škach,Alžbeta Stefela,Josef Škoda,Karel Chalupský,Klára Dohnalová,Ivona Pávková,Thales Kronenberger,Azam Rashidian,Lucie Smutná,Vojtěch Duchoslav,Tomáš Smutný,Petr Pávek,Radim Nencka
标识
DOI:10.1021/acs.jmedchem.2c01140
摘要
The nuclear constitutive androstane receptor (CAR, NR1I3) plays significant roles in many hepatic functions, such as fatty acid oxidation, biotransformation, liver regeneration, as well as clearance of steroid hormones, cholesterol, and bilirubin. CAR has been proposed as a hypothetical target receptor for metabolic or liver disease therapy. Currently known prototype high-affinity human CAR agonists such as CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) have limited selectivity, activating the pregnane X receptor (PXR) receptor, a related receptor of the NR1I subfamily. We have discovered several derivatives of 3-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine that directly activate human CAR in nanomolar concentrations. While compound 39 regulates CAR target genes in humanized CAR mice as well as human hepatocytes, it does not activate other nuclear receptors and is nontoxic in cellular and genotoxic assays as well as in rodent toxicity studies. Our findings concerning potent human CAR agonists with in vivo activity reinforce the role of CAR as a possible therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI